Tuesday, 17 November 2026 SEC EDGAR filings, as they land
ALFA USA News Straight from the SEC filing
SEC Filings
Clinical Trial Data

Aclaris Therapeutics Shares Jump 10% in 9 Days Since Other

Aclaris Therapeutics Reports 45% EASI Improvement in Phase 1b ATI-052 Trial

+10.29% in 9 days $3.79 when we broke this story → $4.18 at 10:32 AM ET, 9 Nov 2026

Aclaris Therapeutics reported positive proof-of-concept data for ATI-052, a bispecific antibody targeting TSLP and IL-4Rα. The drug demonstrated efficacy in both atopic dermatitis and asthma patients while maintaining a favorable safety profile with no observed conjunctivitis.

Analysis, biochemistry, biologist, biology. Stock photo illustrating Aclaris Therapeutics' other story.
Aclaris Therapeutics, Inc. · Healthcare · Photo: Sunriseforever / Pixabay

Key highlights

  • Placebo-adjusted mean improvement of 45% in EASI scores for atopic dermatitis patients at day 57
  • ATI-052 treatment arm achieved 62% mean EASI improvement from baseline by week 10
  • Single dose demonstrated rapid improvements in airway inflammation and lung function for asthma patients
  • Estimated cash and marketable securities of $204.6 million as of September 30, 2026
  • Phase 2b development for eosinophilic esophagitis scheduled to commence in early 2027

Clinical Trial Outcomes

Aclaris Therapeutics reported that ATI-052 met its primary objective in two separate Phase 1b proof-of-concept trials. In the atopic dermatitis study, patients receiving five weekly 480 mg doses experienced significant skin clearance, with clinical effects maintained through week 10. In the asthma cohort, the bispecific antibody achieved rapid improvements in lung function across a diverse patient population. The company estimates its cash, cash equivalents, and marketable securities at approximately $204.6 million as of September 30, 2026, providing liquidity to advance its revised clinical roadmap focused on eosinophilic esophagitis.

Strategic Significance

  • Simultaneous targeting of TSLP and IL-4Ra provides potential synergistic efficacy over single-target monotherapies
  • Absence of conjunctivitis addresses a common safety concern seen in competing IL-4Ra inhibitor treatments
  • Strategic pivot to eosinophilic esophagitis prioritizes an indication with high unmet medical need
  • Proof-of-concept validation supports the potential for broad utility across multiple immuno-inflammatory conditions
  • The results demonstrate early durability and normalization of the immune proteome in heterogeneous disease states

Business and Pipeline Overview

Pennsylvania-based Aclaris Therapeutics is a clinical-stage biopharmaceutical firm specializing in immuno-inflammatory disease treatments. The company pipeline includes ATI-052 and modzatinib, an oral ITK/JAK3 inhibitor currently being evaluated for lichen planus under FDA Fast Track designation. Aclaris recently expanded its portfolio through an exclusive global license agreement with Biosion for ATI-052 and bosakitug. The firm maintains a disciplined capital management strategy, with current cash reserves expected to fund operations and pipeline milestones through the end of 2028.

Financial and Sector Context

Aclaris reported preliminary cash and marketable securities of approximately $204.6 million as of September 30, 2026, an increase from $170.6 million at the end of the second quarter. This growth was assisted by at-the-market equity sales yielding $40.2 million in gross proceeds. The biotechnology sector continues to explore bispecific antibodies to achieve superior efficacy in Th2-mediated diseases. Upcoming milestones for Aclaris include a Phase 2 clinical readout for the anti-TSLP monoclonal antibody bosakitug in moderate-to-severe atopic dermatitis, which is expected in the fourth quarter of 2026.

Aclaris Therapeutics, Inc. share price · last month
Line chart of Aclaris Therapeutics, Inc.'s share price over the last month, from $3.48 on 19 Oct → $3.60 on 16 Nov; our story on 27 Oct at $3.79.

Down 4.9% since our story on 27 Oct: $3.79 when we broke it → $3.60 at the close on 16 Nov. Daily closing prices. Source: Yahoo Finance.

Show the prices
19 Oct$3.48
20 Oct$3.77
21 Oct$3.81
22 Oct$3.83
23 Oct$3.75
26 Oct$3.79
27 Oct$3.79
28 Oct$3.96
29 Oct$3.99
30 Oct$3.97
2 Nov$3.80
3 Nov$3.74
4 Nov$3.68
5 Nov$3.61
6 Nov$3.90
9 Nov$4.24
10 Nov$4.15
11 Nov$4.34
12 Nov$4.00
13 Nov$3.92
16 Nov$3.60

Management Perspective

“These strong results convey the art of the possible with this bispecific mechanism in heterogeneous diseases across diverse patient populations and support that this is a potent, broadly acting compound with potential best-in-class activity.”

Dr. Neal Walker, Chief Executive Officer, Aclaris Therapeutics, Inc.
Earlier announcements by Aclaris Therapeutics, Inc.
DateAnnouncementAmount
06 Aug 2026FDA Fast Track designation granted for modzatinib (ATI-2138) in moderate to severe lichen planusSource: investor.aclaristx.com–
28 Apr 2026Positive full topline Phase 1a results for ATI-052 and selection of lichen planus as lead indication for ATI-2138Source: investor.aclaristx.com–
29 Jul 2025Positive topline results from Phase 2a trial of oral ITK/JAK3 inhibitor ATI-2138 in atopic dermatitisSource: globenewswire.com–
18 Nov 2024Securities purchase agreement for private placement of common stockSource: investor.aclaristx.com$80.0 Million
18 Nov 2024Exclusive global license agreement with Biosion for BSI-045B (bosakitug) and BSI-502 (ATI-052)Source: SEC filing$40.7 Million

Management commentary

“These strong results convey the art of the possible with this bispecific mechanism in heterogeneous diseases across diverse patient populations and support that this is a potent, broadly acting compound with potential best-in-class activity.”

Dr. Neal Walker, Chief Executive Officer
Aclaris Therapeutics, Inc. · financial snapshot
Share price$3.79
Market cap$558M
Revenue (annual)$8M
1-month price change-29.55%
SectorHealthcareBiotechnology

Reference market data from a third-party provider, as of the story. Not a valuation or a recommendation.

Source verified

SEC filing by Aclaris Therapeutics, Inc. announcing positive Phase 1b results for ATI-052.

Read the filing ↗
All Aclaris Therapeutics, Inc. filings and newsView all →

Track Aclaris Therapeutics, Inc. live

Get the next Aclaris Therapeutics, Inc. SEC filing seconds after it lands.

More from Aclaris Therapeutics, Inc.

All →

Get Alerts

Get ALFA Finder alerts first

Real-time SEC filing alerts for US stocks are launching soon. Leave your details and we'll tell you the moment they go live.